Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology

Vascul Pharmacol. 2023 Feb:148:107137. doi: 10.1016/j.vph.2022.107137. Epub 2022 Dec 1.

Abstract

The clinical benefit of LDL cholesterol (LDL-C) lowering for cardiovascular disease prevention is well documented. This paper from the Italian Study Group on Atherosclerosis, Thrombosis and Vascular Biology summarizes current recommendations for treatment of hypercholesterolemia, barriers to lipid-lowering therapy implementation and tips to overcome them, as well as available evidence on the efficacy and safety of bempedoic acid. We also report an updated therapeutic algorithm for pharmacological LDL-C lowering in view of the introduction of bempedoic acid in clinical practice.

Keywords: Bempedoic acid; Dyslipidaemia; LDL cholesterol.

Publication types

  • Review

MeSH terms

  • Atherosclerosis* / diagnosis
  • Atherosclerosis* / drug therapy
  • Atherosclerosis* / prevention & control
  • Biology
  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / prevention & control
  • Cholesterol, LDL
  • Consensus
  • Fatty Acids
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Risk Factors
  • Thrombosis* / drug therapy
  • Thrombosis* / prevention & control

Substances

  • Cholesterol, LDL
  • 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
  • Fatty Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors